• Monthly
  • $25
  • $50
  • $100
  • $other
  • use PayPal

ONE WEEK TO DOUBLE YOUR DONATION!

A generous CounterPuncher has offered a $25,000 matching grant. So for this week only, whatever you can donate will be doubled up to $25,000! If you have the means, please donate! If you already have done so, thank you for your support. All contributions are tax-deductible.
FacebookTwitterRedditEmail

Bush Report on Drug Imports

Some recent headlines:

“HHS reports drug imports likely won’t save money.”

“Net saving on drug import not worth action.”

“Legalizing drug imports not worth it.”

“Bush panel sees scant savings in drug imports.”

These were based on a report released two weeks ago by the Department of Health and Human Services which concluded that “total savings to drug buyers from legalized commercial importation would be 1 to 2 percent of total drug spending.”

If this were true, reimportation of drugs would never take off. Why, then, would the drug industry spend so much time fighting this plan? What is it that the drug companies know but that the Department of Health and Human Services doesn’t want you to understand?

The answer is that the data in the report don’t support the department’s conclusions.

The research in the report actually indicates the possibility of saving 17.5 percent, or $37.8 billion, annually in the United States. And this also explains the drug industry’s fear of importation.

The department’s conclusion that reimportation will not result in significant savings is built on the premise as stated in the report that “imported drugs may be around 12 percent of total use … because drug companies have incentives to impede exports.” This assumption doesn’t take into account that reimportation bills would make it illegal to limit supply something the drug companies are keenly aware of but the Department of Health and Human Services completely forgot.

The second faulty premise is that “U.S. drug buyers may get discounts of only 20 percent or less, with the rest of the difference between U.S. and foreign prices going to commercial importers.”

This statement should be contrasted with a chart in the report showing that U.S. retail drug prices are 100 percent higher than in Europe. So this premise assumes unprecedented price gouging by importers and a complete lack of competition among them. Of course, the drug industry knows that is not how the free market works, but the Department of Health and Human Services feigns ignorance.

The third premise in the report is that “about 30 percent of total drug spending may be unchanged by legalizing commercial importation because about that much is now spent on products that are inappropriate for importation.” According to the report, these would include such drugs as those used during surgery, those that are injected, controlled substances or low-cost generics.

Let’s now do the analysis of savings possible in the United States, based on the data in the report. We know that according to the report drug prices in Europe are at least 50 percent lower than in the United States. Let’s be very conservative and assume as much as half of this price difference is captured by greedy importers a pretty unlikely scenario because with such costs, reimportation would never have existed within Europe.

Then we take the report’s premise that 30 percent of the U.S. market will not have competition from reimported drugs because they are generics or belong to categories that can’t be imported easily.

That leaves 70 percent of the market multiplied by a 25 percent price reduction, for a saving of 17.5 percent on the total U.S. drug bill of $216 billion, resulting in a net saving of $37.8 billion.

This is a simplified analysis, but more complex mathematical models based on the Department of Health and Human Services’ research data result in similar savings. In summary, the report has the right data but the wrong conclusions.

PETER ROST is a vice president of marketing at Pfizer; the views expressed here are his own.

More articles by:
bernie-the-sandernistas-cover-344x550
Weekend Edition
October 18, 2019
Friday - Sunday
Anthony DiMaggio
Trump as the “Anti-War” President: on Misinformation in American Political Discourse
Jeffrey St. Clair
Roaming Charges: Where’s the Beef With Billionaires?
Rob Urie
Capitalism and the Violence of Environmental Decline
Paul Street
Bernie in the Deep Shit: Dismal Dem Debate Reflections
Andrew Levine
What’s So Awful About Foreign Interference?
T.J. Coles
Boris Johnson’s Brexit “Betrayal”: Elect a Clown, Expect a Pie in Your Face
Joseph Natoli
Trump on the March
Ashley Smith
Stop the Normalization of Concentration Camps
Pete Dolack
The Fight to Overturn the Latest Corporate Coup at Pacifica Has Only Begun
Jeremy Kuzmarov
Russophobia at Democratic Party Debate
Chris Gilbert
Forward! A Week of Protest in Catalonia
Daniel Beaumont
Pressing Done Here: Syria, Iraq and “Informed Discussion”
Daniel Warner
Greta the Disturber
M. G. Piety
“Grim Positivism” vs. Truthiness in Biography
John Kendall Hawkins
Journey to the Unknown Interior of (You)
Christopher Fons – Conor McMullen
The Centrism of Elizabeth Warren
Nino Pagliccia
Peace Restored in Ecuador, But is trust?
Rebecca Gordon
Extorting Ukraine is Bad Enough But Trump Has Done Much Worse
Kathleen Wallace
Trump Can’t Survive Where the Bats and Moonlight Laugh
Clark T. Scott
Cross-eyed, Fanged and Horned
Eileen Appelbaum
The PR Campaign to Hide the Real Cause of those Sky-High Surprise Medical Bills
Olivia Alperstein
Nuclear Weapons are an Existential Threat
Colin Todhunter
Asia-Pacific Trade Deal: Trading Away Indian Agriculture?
Sarah Anderson
Where is “Line Worker Barbie”?
Brian Cloughley
Yearning to Breathe Free
Jill Richardson
Why are LGBTQ Rights Even a Debate?
Jesse Jackson
What I Learn While Having Lunch at Cook County Jail
Kathy Kelly
Death, Misery and Bloodshed in Yemen
Maximilian Werner
Leadership Lacking for Wolf Protection
Arshad Khan
The Turkish Gambit
Kollibri terre Sonnenblume
Rare Wildflower vs. Mining Company
Dianne Woodward
Race Against Time (and For Palestinians)
Norman Ball
Wall Street Sees the Light of Domestic Reindustrialization
Ramzy Baroud
The Last Lifeline: The Real Reason Behind Abbas’ Call for Elections
Binoy Kampmark
African Swine Fever Does Its Worst
Nicky Reid
Screwing Over the Kurds: An All-American Pastime
Louis Proyect
“Our Boys”: a Brutally Honest Film About the Consequences of the Occupation
Coco Das
#OUTNOW
Cesar Chelala
Donald Trump vs. William Shakespeare
Ron Jacobs
Calling the Kettle White: Ishmael Reed Unbound
Stephen Cooper
Scientist vs. Cooper: The Interview, Round 3 
Susan Block
How “Hustlers” Hustles Us
Charles R. Larson
Review: Elif Shafak’s “10 Minutes 38 Seconds in This Strange World”
David Yearsley
Sunset Songs
October 17, 2019
Steve Early
The Irishman Cometh: Teamster History Hits the Big Screen (Again)
FacebookTwitterRedditEmail